Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.

Status Completed

Clinical Trial Summary

This study seeks to evaluate the effect of topical aqueous suppression on the anatomic and functional response to intravitreal anti-vascular endothelial growth factor (VEGF) injections in non-responders with wet age-related macular degeneration.

Clinical Trial Description

Intravitreal anti-vascular endothelial growth factor (VEGF) agents, including bevacizumab, ranibizumab, and aflibercept, have become the gold standard treatment for neovascular age-related macular degeneration (AMD). Various treatment modalities using these agents have been proposed, including monthly, pro re nata, and treat-and-extend philosophies. Despite frequent and consistent treatment with anti-VEGF therapy, there is a subset of patients who are incomplete or non-responders and have persistent evidence of exudation on spectral-domain optical coherence tomography (SD-OCT), including subretinal fluid (SRF) and/or intraretinal edema.

While clearance of intravitreal anti-VEGF drugs is not completely understood, some studies have suggested that outflow through the anterior chamber may contribute. We hypothesized that by decreasing aqueous production, outflow may also be reduced which could delay the clearance of intravitreal drugs. As a result, we chose topical dorzolamide-timolol since it is a potent aqueous suppressant and is readily available due to its common use in the treatment of glaucoma. The current study aimed to evaluate the efficacy of topical dorzolamide-timolol on anatomic and visual outcomes in anti-VEGF non-responders with neovascular AMD.

Significance: The results of this study will help delineate whether topical aqueous suppression may be useful as adjuvant therapy in patients receiving chronic intravitreal anti-VEGF injections. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02571972
Study type	Interventional
Source	Wills Eye
Contact
Status	Completed
Phase	Phase 2
Start date	February 1, 2015
Completion date	December 20, 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03953807` - A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated	Phase 4
Completed	`NCT03622580` - A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)	Phase 3
Recruiting	`NCT06262737` - Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
Terminated	`NCT04611152` - A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)	Phase 3
Terminated	`NCT04603937` - A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)	Phase 3
Active, not recruiting	`NCT04108156` - This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab	Phase 3
Completed	`NCT02867735` - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema	Phase 1
Withdrawn	`NCT03629210` - Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema	Phase 2
Withdrawn	`NCT02842541` - Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema	Phase 1
Completed	`NCT02221453` - Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide	Phase 2
Completed	`NCT02979665` - Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema
Completed	`NCT02556723` - Intravitreal Injections of Ziv-aflibercept for Macular Diseases	N/A
Completed	`NCT02000102` - Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab	N/A
Completed	`NCT02088229` - Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema	N/A
Terminated	`NCT00779142` - Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies	N/A
Completed	`NCT01171976` - Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus	Phase 3
Completed	`NCT00989989` - Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema	Phase 3
Completed	`NCT01259609` - Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy	N/A
Completed	`NCT00683176` - Effect of Choline Fenofibrate (SLV348) on Macular Edema	Phase 2
Terminated	`NCT00768040` - Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema	Phase 2